Am I right in reading that xref credits used went up 100k from 3.7 mil (Q1) to 3.8 million (q2) while rapid I'd use increased from 200k (Q1) to 500k (q2) net. While cash sales are down. The actual revenue is up on last quarter. Historically q2 and Q3 are similar but with actual usage and there for revenue going up those credits need to be renewed who knows. The rapid I'd with the benefit of hindsight looks to be paying off .
- Forums
- ASX - By Stock
- XF1
- Ann: Xref achieves 71% Sales Growth & $0.2m Cash Surplus Q2FY22
XF1
xref limited
Add to My Watchlist
3.23%
!
16.0¢

Ann: Xref achieves 71% Sales Growth & $0.2m Cash Surplus Q2FY22, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
16.0¢ |
Change
0.005(3.23%) |
Mkt cap ! $35.21M |
Open | High | Low | Value | Volume |
15.5¢ | 16.0¢ | 15.5¢ | $9.154K | 57.22K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 12681 | 15.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
16.0¢ | 143201 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 12681 | 0.150 |
3 | 96000 | 0.130 |
1 | 500000 | 0.125 |
2 | 60000 | 0.120 |
1 | 28575 | 0.105 |
Price($) | Vol. | No. |
---|---|---|
0.160 | 143201 | 1 |
0.165 | 153136 | 4 |
0.170 | 242000 | 2 |
0.180 | 41059 | 1 |
0.230 | 47500 | 1 |
Last trade - 16.10pm 01/07/2025 (20 minute delay) ? |
Featured News
XF1 (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Dr. Steven Gourlay, CEO
Dr. Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online